These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1536 related items for PubMed ID: 23645542

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
    Kurozumi S, Inoue K, Takei H, Matsumoto H, Kurosumi M, Horiguchi J, Takeyoshi I, Oyama T.
    BMC Cancer; 2015 Sep 07; 15():622. PubMed ID: 26345461
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Correlation of Preoperative Ki67 and Serum CA15.3 Levels with Outcome in Early Breast Cancers a Multi Institutional Study.
    Rasmy A, Abozeed W, Elsamany S, Baiomy ME, Nashwa A, Amrallah A, Hasaan E, Alzahrani A, Faris M, Alsaleh K, AlFaraj A.
    Asian Pac J Cancer Prev; 2016 Sep 07; 17(7):3595-600. PubMed ID: 27510014
    [Abstract] [Full Text] [Related]

  • 7. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.
    Cancer; 2010 Sep 15; 116(18):4227-37. PubMed ID: 20549829
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
    Lv M, Li B, Li Y, Mao X, Yao F, Jin F.
    Asian Pac J Cancer Prev; 2011 Sep 15; 12(9):2411-7. PubMed ID: 22296393
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N, Deligonul A, Tolunay S, Cubukcu E, Fatih Olmez O, Ulas A, Hartavi M, Kurt E, Evrensel T.
    J BUON; 2015 Sep 15; 20(1):45-9. PubMed ID: 25778295
    [Abstract] [Full Text] [Related]

  • 14. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.
    Asian Pac J Cancer Prev; 2012 Sep 15; 13(8):4119-23. PubMed ID: 23098527
    [Abstract] [Full Text] [Related]

  • 15. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L, Morabito F, Provinciali N, Canobbio L, Meszaros P, Naso C, Murialdo R, Boitano M, Salvi S, Ferrarini M.
    Eur J Surg Oncol; 2013 Oct 15; 39(10):1046-52. PubMed ID: 23890870
    [Abstract] [Full Text] [Related]

  • 16. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G.
    Breast Cancer Res; 2009 Oct 15; 11(5):R69. PubMed ID: 19758440
    [Abstract] [Full Text] [Related]

  • 17. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ, Park IA, Song IH, Kim SB, Jung KH, Ahn JH, Ahn SH, Kim HH, Gong G.
    PLoS One; 2015 Oct 15; 10(9):e0137885. PubMed ID: 26394326
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L, Vanella P, Canobbio L, Naso C, Cerisola N, Meszaros P, Parodi MA, Morabito F.
    Oncology; 2010 Oct 15; 79(3-4):255-61. PubMed ID: 21372600
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
    Yagi T, Inoue N, Yanai A, Murase K, Imamura M, Miyagawa Y, Enomoto Y, Nishimukai A, Takatsuka Y, Hirota S, Akazawa K, Miyoshi Y.
    Breast Cancer; 2016 Mar 15; 23(2):224-30. PubMed ID: 25082658
    [Abstract] [Full Text] [Related]

  • 20. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
    Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.
    Clin Breast Cancer; 2013 Apr 15; 13(2):146-52. PubMed ID: 23318089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.